LY 03021
Alternative Names: LY-03021Latest Information Update: 24 Mar 2025
At a glance
- Originator Luye Pharma Group
- Class Antidepressants; Antipsychotics; Small molecules
- Mechanism of Action Dopamine plasma membrane transport protein antagonists; GABA A receptor positive allosteric modulators; Norepinephrine plasma membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Schizophrenia
- Preclinical Major depressive disorder
Most Recent Events
- 24 Mar 2025 Phase-I clinical trials in Alzheimer's disease in China (unspecified route) (Luye Pharma pipeline, March 2025 )
- 24 Mar 2025 Phase-I clinical trials in Schizophrenia in China (unspecified route) (Luye Pharma pipeline, March 2025 )
- 15 Nov 2024 Luye Phrama Group plans a clinical trial in Major Depressive disorder in China